Professor Giovanni Lorenzini founded IBI in 1918.  An open-minded business man and great innovator, Lorenzini made a name for the company with the first multivitamin product and covered the national requirements for ascorbic acid, thiamine and insulin in the interwar period. A life devoted to research, he saw industry as: “Applied science [whose] noble intents and dignified form it has to maintain”. In the period of the two world wars, when industry and society were asked to take part in rebuilding the country, he made the motto “Fareperdare” (create to contribute) the company philosophy. Still run by the same family, this motto remains at the basis of the company’s day-to-day activities today.



In 1936, confirming its strong international vocation, IBI is already present abroad, in Brazil. Today it exports 2/3 of its turnover worldwide.

In 1940, the founder’s death ushered in the era of “female management”, introducing a new feature that immediately became a key success factor: the development of ethical drugs, followed by exports and the internal production of antibiotics.


Since 1956 IBI has been researching, developing and patenting innovative production methods for a range of antibiotics and today it is a leader on the sterile penicillin and injectable drugs market.


In 1961, it was one of the first companies in Italy to obtain FDA certification for the exportation of ß-lactam antibiotics.

The 1970s marked the beginning of a period of know-how transfer which saw the construction of important antibiotic production plants abroad (Algeria, Cuba, Nigeria, Egypt and Panama).


In 1974 IBI opened the production unit in Aprilia, today the company headquarters. In the 1980s, under the guidance of the tenacious and determined Loredana Lorenzini, the company became one of the leading pharmaceutical industries on the Italian stage.


In 1990 there was a new generational change. Loredana Lorenzini was succeeded by her niece Camilla Borghese Khevenhüller, the current chairperson and managing director, who has reorganized the company and renewed the product range, while strengthening the sales structure in Italy.

The 1990s were marked by a series of important patents (amongst which silybin complex, amoxicillin crystal, piperacillin precipitate, ursodeoxycholic acid and others), up to the launch of Realsil in 2001; these achievements made IBI, now an exporter of both raw materials and finished products, a world-famous, high-quality brand.


In 2006 IBI created a distribution strategy in hospitals, entrusting the sales of its products to a specialized distribution system, the Ibisqus Hospital Line, present today in Italy, the UK, Germany and Ireland.


In 2007 IBI opened a new building entirely dedicated to the production of ß-lactam drugs.

In 2015 the department for recombinant protein production and biological dosage for clinical trials received authorization from the AIFA (Italian Drug Agency).

Thank you

We sent you an email. To activate the newsletter click on the link you will find in the message, thank you!


Private area

Log in to restricted area


Notice on the treatment of personal data

Dear visitor, in the following sections we will describe how the reserved area of the website is managed as far as processing personal data of users. The notice is issued pursuant to art. 13 of EU Regulation 679/2016 (hereinafter also the Regulation) on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and applies to those who interact with the website of Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. (hereinafter I.B.I.), which can be accessed at the following address:, the opening page of the official I.B.I. website. The notice only applies to the I.B.I. website. It does not apply to any other websites that the user may access through links.

  1. The processing of the personal data that you supply, which are also used for the creation of your user profile, and which will be included in the “Doctors’ Details” database, has the following purposes:
  • carry out medical sales related activities for drugs for human consumption. Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. and Ibigen S.r.l., part of the same company group (hereinafter also Ibigen Group), carry out such activities in compliance with the provisions of the current regulations, with particular, but not exclusive, attention to Italian Legislative Decree no. 219 of 24.04.2006 and subsequent modifications. In view of the objectives of the Ibigen Group, it is important to point out that the processing activities do not deal with any special data. The supply of the data for the medical sales activities is necessary, and failure to provide consent will make it impossible for us to fulfil the above objectives;

  • forwarding of invitations or information on congresses, conferences, seminars, communications on initiatives promoted or sponsored by the Ibigen group, regular or occasional publications, information on new products, methods and services. Such activities are carried out by e-mail, fax, SMS, normal post or telephone. The supply of the data for such purposes is optional, and failure to supply them will result in the information not being forwarded.

  1. As far as the creation of your profile on our website, we remind you that your password is strictly confidential and should not be disclosed.
  2. Your data will not be disclosed, but may be shared with individuals, companies, associations or professional studios providing support or consultancy services to the Ibigen Group, the medical sales representative network, our suppliers and any sub-suppliers - from time to time entrusted with activities connected with the above objectives -, mailing or statistical survey companies, or companies for the forwarding of scientific documentation, and individuals authorised to access the data by law and/or pursuant to secondary regulations.
  3. Such people may only acquire knowledge of your personal data for the above mentioned purposes.
  4. The Owners of the Treatment (Data Controllers) are the two companies of the Ibigen Group with legal headquarters at Via Fossignano no. 2, Aprilia (LT), Italy.
  5. Personal data are processed using manual and automated means, for the time necessary for reaching the objectives for which they were collected. Special safety measures are in place to avoid data loss, unlawful or incorrect use and unauthorised access.
  6. Lastly, we also inform you that you can at any time exercise the rights contemplated by the Regulation, and in particular request access to the data, their correction, update and block, or you can withdraw your consent, or request the limitation of the processing or the cancellation of the data. As data subject, you also have the right to issue a complaint with the relevant control Authority. Such rights may be exercised in writing to the following e-mail address:
  7. The Data Protection Officer may be contacted at the following e-mail address:

* Required fields